Сравнение
Cagrilintide vs. Setmelanotide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
1415456-99-3
920014-72-8
Молекулярная масса
4253.7 g/mol
1117.32 g/mol
Период полувыведения
168 h
11 h
Последовательность
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYAc-Arg-Cys(1)-D-Ala-His-D-Phe-Arg-Trp-Cys(1)-NH2 (zyklisches Oktapeptid, Disulfidbrücke Cys2–Cys8)Механизм действия
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Setmelanotide
Setmelanotide is an agonist at the melanocortin-4 receptor (MC4R), a central receptor of the hypothalamic melanocortin pathway involved in the control of energy balance, satiety and body weight. In certain genetic defects (e.g. in POMC, PCSK1 or LEPR), the natural activation of MC4R is reduced. Setmelanotide activates MC4R directly, thereby bypassing the upstream defect. This description is mechanistic and neutral and does not constitute a recommendation for use.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
4
4
из них на людях
3
3
Зафиксированные эффекты
3
3
Открытые противоречия
1
1
Задокументированные нежелательные явления
1
3
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Cagrilintide and Setmelanotide?
- Cagrilintide is classified as "Метаболизм", while Setmelanotide is classified as "Метаболизм". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Setmelanotide: Setmelanotide (brand name Imcivree) is a synthetic cyclic octapeptide and an agonist at the melanocortin-4 receptor (MC4R). It was developed and approved as a prescription medicine for chronic weight management in rare genetic forms of obesity within the MC4R signalling pathway (including POMC, PCSK1 and LEPR deficiency as well as Bardet-Biedl syndrome). The following information is provided for informational and educational purposes only. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Cagrilintide or Setmelanotide?
- The highest available evidence level is "РКИ на людях" for Cagrilintide and "РКИ на людях" for Setmelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Cagrilintide and Setmelanotide in Germany and the United States?
- Германия: Cagrilintide — Не одобрено, Setmelanotide — Рецептурный. США: Cagrilintide — Не одобрено, Setmelanotide — Рецептурный. These are factual summaries with source and review date on the individual pages.